Loading...
Market
Which disease area will DeepRVAT's first major breakthrough be in?
2
Resolution / Starting Odds
Cancer • 25%
Cardiovascular Disease • 25%
Neurological Disorders • 25%
Other • 25%
Published research studies, official announcements
Story
DKFZ, EMBL, TU Muenchen Develop AI Model DeepRVAT for Rare Variant Testing
Sep 26, 2024, 06:12 AM
Researchers at DKFZ, EMBL, and TU Muenchen have developed a new AI model called DeepRVAT. This model leverages deep set neural networks to integrate variant annotations, enhancing the accuracy of rare variant association testing. DeepRVAT allows for more precise distinction of individuals at high risk of disease and helps identify genes involved in disease development. The model first accounts for nonlinear effects from rare variants on gene function and then models variation in traits as linear functions of estimated gene impairment scores. This breakthrough, developed in collaboration with Holtkamp_Eva and brianfclarke, pushes the boundaries of personalized medicine by providing more accurate predictions of the effects of rare genetic variants. The model also harnesses variant annotations from models like AlphaMissense.
View original story
Similar markets
Cancer treatment • 25%
Neurodegenerative diseases • 25%
Infectious diseases • 25%
Cardiovascular diseases • 25%
Cancer • 25%
Cardiovascular disease • 25%
Neurological disorder • 25%
Other • 25%
Cancer • 25%
Neurodegenerative Diseases • 25%
Cardiovascular Diseases • 25%
Other • 25%
Cardiovascular • 25%
Oncology • 25%
Neurology • 25%
Other • 25%
Genetic Disorders • 25%
Infectious Diseases • 25%
Neurological Disorders • 25%
Other • 25%
Cancer treatment • 25%
Neurodegenerative disease treatment • 25%
Cardiovascular disease treatment • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
Breast Cancer Diagnosis • 25%
Lung Cancer Diagnosis • 25%
Prostate Cancer Diagnosis • 25%
Other • 25%
Drug discovery • 25%
Agricultural biotechnology • 25%
Industrial biotechnology • 25%
Other • 25%
Breast Cancer • 25%
Lung Cancer • 25%
Prostate Cancer • 25%
Other • 25%
Pneumonia • 25%
Asthma • 25%
Chronic Obstructive Pulmonary Disease (COPD) • 25%
Other • 25%
Lung function estimation • 25%
Coronary calcium score • 25%
Heart ejection fraction • 25%
Type 2 diabetes diagnosis • 25%